VJHemOnc is committed to improving our service to you

ICML 2019 | Adding acalabrutinib to the arsenal: impact of ASCEND in CLL

VJHemOnc is committed to improving our service to you

Barbara Eichhorst

Barbara Eichhorst, MD, University Hospital of Cologne, Cologne, Germany, discusses the ASCEND trial (NCT02970318) of acalabrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), and the potential impact of the results on clinical practice. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter